IDEXX Laboratories, Inc. (IDXX) Shares Sold by Hanseatic Management Services Inc.
Hanseatic Management Services Inc. decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 50.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,294 shares of the company’s stock after selling 8,604 shares during the period. IDEXX Laboratories comprises about 1.5% of Hanseatic Management Services Inc.’s investment portfolio, making the stock its 12th biggest holding. Hanseatic Management Services Inc.’s holdings in IDEXX Laboratories were worth $1,290,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of the business. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its holdings in shares of IDEXX Laboratories by 2.7% in the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 21,544 shares of the company’s stock worth $3,350,000 after purchasing an additional 558 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of IDEXX Laboratories by 30.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 955,225 shares of the company’s stock worth $148,527,000 after purchasing an additional 220,818 shares in the last quarter. DekaBank Deutsche Girozentrale increased its holdings in shares of IDEXX Laboratories by 17.6% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 19,090 shares of the company’s stock worth $3,032,000 after purchasing an additional 2,855 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of IDEXX Laboratories by 1.1% in the 3rd quarter. Rhumbline Advisers now owns 188,074 shares of the company’s stock worth $29,244,000 after purchasing an additional 2,001 shares in the last quarter. Finally, Strategy Asset Managers LLC bought a new stake in shares of IDEXX Laboratories in the 3rd quarter worth $2,457,000. 88.03% of the stock is owned by institutional investors and hedge funds.
In related news, Director Rebecca M. Henderson sold 2,578 shares of IDEXX Laboratories stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $152.86, for a total transaction of $394,073.08. Following the transaction, the director now directly owns 17,274 shares in the company, valued at $2,640,503.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Rebecca M. Henderson sold 5,156 shares of IDEXX Laboratories stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $153.29, for a total value of $790,363.24. Following the transaction, the director now owns 17,274 shares in the company, valued at $2,647,931.46. The disclosure for this sale can be found here. Insiders sold 92,734 shares of company stock valued at $14,083,486 in the last ninety days. 2.77% of the stock is currently owned by corporate insiders.
Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) traded up $1.75 on Wednesday, hitting $149.54. The company had a trading volume of 668,500 shares, compared to its average volume of 713,802. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48. IDEXX Laboratories, Inc. has a one year low of $109.35 and a one year high of $173.01. The company has a market capitalization of $13,090.00, a price-to-earnings ratio of 49.76, a P/E/G ratio of 2.23 and a beta of 0.46.
IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The company had revenue of $492.00 million during the quarter, compared to analyst estimates of $492.94 million. During the same quarter in the previous year, the company posted $0.62 earnings per share. IDEXX Laboratories’s revenue was up 9.7% compared to the same quarter last year. research analysts anticipate that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current fiscal year.
A number of research firms have commented on IDXX. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 target price for the company in a report on Tuesday, October 24th. Stifel Nicolaus reissued a “buy” rating and issued a $185.00 target price on shares of IDEXX Laboratories in a report on Tuesday, October 24th. Canaccord Genuity reissued a “buy” rating and issued a $180.00 target price on shares of IDEXX Laboratories in a report on Friday, October 6th. Bank of America Corporation raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price objective for the company in a report on Wednesday, August 23rd. Finally, BidaskClub lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $173.67.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Stock Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related stocks with our FREE daily email newsletter.